3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
2
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
durvalumab
7
Gemcitabine
7
Oxaliplatin
6
Magnetic Resonance Spectroscopy
6
Leucovorin
6
Cisplatin
6
Specimen Handling
5
Fluorouracil
5
Biopsy
5
Paclitaxel
4
Folfox protocol
4
Irinotecan
3
pemigatinib
2
pembrolizumab
2
olaparib
2
futibatinib
2
fludarabine
2
dehydroftorafur
2
Taxes
2
Nivolumab
2
Immunoglobulin G
2
Fluorodeoxyglucose F18
2
Disulfides
2
Carboplatin
2
zimberelimab
1
zanidatamab
1
ulixertinib
1
tremelimumab
1
trametinib
1
tocilizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.